Apolipoprotein C-III (Apo C-III) Assay
Apolipoprotein C-III (Apo C-III) Assay
Reagent | Apolipoprotein C-III (Apo C-III)
An Independent Risk Factor for CVD
Benefits of the Randox Apo C-lll Assay

Immunoturbidimetric method
The immunoturbidimetric method limits interference from Bilirubin, Haemoglobin, Intralipid® and Triglycerides, producing more accurate results.

Exceptional correlation
A correlation coefficient of r=1.00 was displayed when the Randox apo C-III assay was compared to commercially available methods.

Excellent measuring range
The Randox apo C-III assay has a measuring range of 2.06 – 21.7mg/dl for the comfortable detection of clinically important results.

Liquid ready-to-use
The Randox apo C-III assay is available in a liquid ready-to-use format for convenience and ease-of-use.

Dedicated calibrator and controls available
Randox offer dedicated apolipoprotein calibrator and controls for a complete testing package.

Applications available
Applications available detailing instrument-specific settings for the convenient use of the Randox apo C-III assay on a variety of clinical chemistry analysers.
Ordering Information
Cat No | Size | ||||
---|---|---|---|---|---|
LP3865 | R1 2 x 11ml R2 2 x 5ml | Enquire | Kit Insert Request | MSDS | Buy Online |
Instrument Specific Applications (ISA’s) are available for a wide range of biochemistry analysers. Contact us to enquire about your specific analyser.
Clinical Significance
Not only is apo C-III a key regulator in the metabolism of triglycerides, but it is also an independent risk factor for CVD. Not only does apo C-III contribute to CVD through the regulation of triglycerides but also through its direct atherogenic effects, promoting atherosclerosis (fig 1) 1.
Fig. 1. Pleiotropic effects of apo C-III 1

Physiological Significance
Apo C-III is composed of 79 amino acids and has a molecular weight of 8.8kDa. Apo C-III promotes hypertriglyceridemia via several mechanisms. Firstly, like apo C-II, apo C-III also inhibits the activity of LPL, distributing lipid lipolysis. Apo C-III hinders the binding of apolipoprotein B and apolipoprotein E to the hepatic receptors resulting in the delayed catabolism of triglyceride – rich lipoproteins (TRLs). Finally, apo C-III prefers the production and secretion of very low-density lipoproteins (VLDL) in the liver 1.
Useful links
Reagents Home
Apolipoprotein Control
Apolipoprotein Calibrator
Archives
- June 2022
- May 2022
- March 2022
- February 2022
- January 2022
- December 2021
- November 2021
- October 2021
- September 2021
- August 2021
- July 2021
- June 2021
- May 2021
- April 2021
- March 2021
- February 2021
- January 2021
- December 2020
- November 2020
- October 2020
- September 2020
- August 2020
- July 2020
- June 2020
- May 2020
- April 2020
- March 2020
- February 2020
- January 2020
- December 2019
- November 2019
- October 2019
- September 2019
- August 2019
- July 2019
- June 2019
- May 2019
- April 2019
- March 2019
- February 2019
- January 2019
- December 2018
- November 2018
- October 2018
- September 2018
- August 2018
- July 2018
- June 2018
- May 2018
- April 2018
- March 2018
- February 2018
- January 2018
- December 2017
- November 2017
- October 2017
- September 2017
- August 2017
- July 2017
- June 2017
- May 2017
- April 2017
- March 2017
- February 2017
- January 2017
- December 2016
- November 2016
- October 2016
- September 2016
- August 2016
- July 2016
- June 2016
- May 2016
- April 2016
- March 2016
- February 2016
- January 2016
- December 2015
- July 2015
- June 2015
- May 2015
- April 2015
- March 2015
- February 2015
- January 2015
- December 2014
- November 2014
- October 2014
- September 2014
- July 2014
- June 2014